Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

p14 ARF protein also regulates tumor-induced angiogenesis

Researchers at Winship Cancer Institute of Emory University have identified a new function for a gene that normally prevents the development of cancer.

2 Mar 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Combined bioactive peptides successfully stimulate wound healing

Researchers have combined bioactive peptides to successfully stimulate wound healing. The in vitro and in vivo study, published today in PLoS ONE, demonstrates that the combination of two peptides stimulates the growth of blood vessels and promotes re-growth of tissue. Further development of these peptides could lead to a new treatment for chronic and acute wounds.

24 Feb 2012

Low dose carbon monoxide therapy can prevent fetal death

Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.

19 Feb 2012

UCSF stem cell study suggests novel strategy for heart attack

A UCSF stem cell study conducted in mice suggests a novel strategy for treating damaged cardiac tissue in patients following a heart attack. The approach potentially could improve cardiac function, minimize scar size, lead to the development of new blood vessels - and avoid the risk of tissue rejection.

16 Feb 2012

TFF3 protein plays a more sinister role in breast cancer metastasis

The trefoil factor 3 (TFF3) protein protects and maintains the integrity of the epithelial surface in the normal breast. New research has found that while TFF3 protein expression is higher in well-differentiated low grade tumors and therefore associated with features of a good prognosis, it has a more sinister role in breast cancer invasion and metastasis.

16 Feb 2012

Cancer cell communication signals may contain pieces of RNA

Researchers have shown that the communication signals sent around the body by cancer cells, which are essential for the cancer to grow, may contain pieces of RNA - these substances, like DNA, are pieces of genetic code that can instruct cells, and ultimately the body, how to form. The same study also found early indications that these genetic instructions can be intercepted and modified by chemotherapy to help prevent cancer cells growing.

16 Feb 2012

Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.

15 Feb 2012

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy.

15 Feb 2012

Tiltan initiates TL-118 Phase 2 clinical trial for pancreatic cancer

Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Researchers discover function and expression of CD97 in malignant gliomas

Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center and Old Dominion University have discovered that suppression of Wilms tumor 1 protein (WT1) results in downregulation of CD97 gene expression in three glioblastoma cell lines and reduces the characteristic invasiveness exhibited by glial tumor cells.

8 Feb 2012

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Lycopene can kill prostate cancer cells

A nutrient in cooked tomatoes has been shown in laboratory studies to slow the growth of or even kill prostate cancer cells.

31 Jan 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

Susan Mallery finds breakthrough treatment for oral cancer

Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer.

30 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012